Hutch News
Results per Page:
Tip Sheet: Diversity in vaccine clinical trials, behind-the-scenes look at COVID-19 biostats, new cell therapy approved, plus meet ‘Megasphaera hutchinsoni’
Summaries of recent Fred Hutch research findings and other news
What's next for T-cell therapies: Q&A with Dr. Stanley Riddell
After approval of latest cellular therapy for non-Hodgkin lymphoma, the immunologist looks ahead
Fred Hutch statement regarding the FDA approval of CD19 immunotherapy, lisocabtagene maraleucel
The newly-approved CAR T-cell therapy was developed in part by Fred Hutch physician-scientists
Mariners honor cancer survivor Colin Craig
Seattle native works to support lifesaving research — like the immunotherapy that put his cancer in remission
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
Fred Hutch immunotherapy expert comments on FDA staff review of CAR T-cell therapy
Key stories of Fred Hutch research from 2016
A roundup of some of our favorite 2016 stories on research at Fred Hutch
'A place where miracles happen': Opening of Bezos Family Immunotherapy Clinic highlights patient-focused science
Research symposium and ribbon cutting celebrates first-of-its-kind facility for experimental immunotherapies
Fred Hutch opens first-of-its kind Bezos Family Immunotherapy Clinic
Clinic will allow researchers to conduct twice as many immunotherapy trials, enable intensive patient monitoring to improve experimental therapies
Physician-scientist Dr. Bruce Clurman named executive vice president and deputy director of Fred Hutch
Clurman will focus on team science, interdisciplinary collaboration in pursuit of new cures, said President and Director Dr. Gary Gilliland
Good News: Dr. David Maloney named cellular immunotherapy medical director at Fred Hutch, SCCA; Dr. Jim Kublin gets grant to study how gut bugs alter HIV vaccine response
Celebrating faculty and staff achievements
Patients with advanced lymphoma in remission after T-cell therapy
New study: 7 of 11 trial participants who got two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission
Good News at Fred Hutch: Immunotherapy pioneer named chair, Nobel laureate keynotes
Celebrating faculty and staff achievements
93 percent of advanced leukemia patients in remission after immunotherapy
‘Exciting’ but early results from trial of engineered immune cells
Dramatic remissions seen in immunotherapy trial of blood cancer patients
Experimental, living T-cell therapy shows promise for treating advanced disease, making immunotherapy a ‘pillar’ of cancer care